Rapport Therapeutics, Inc. has entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities $(USA)$ LLC, and Stifel, Nicolaus & Company, Incorporated for a public offering of 9,615,385 shares of its common stock. Priced at $26.00 per share, the offering is expected to generate approximately $234.7 million in net proceeds, excluding potential additional shares the underwriters may purchase. The funds will be used to support ongoing and planned clinical trials, research and development initiatives, and general corporate purposes. The offering is anticipated to close around September 11, 2025, pending customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-200205), on September 10, 2025, and is solely responsible for the information contained therein.